Cancer types · Other solid tumours
Kidney Cancer
Most kidney cancers are renal cell carcinomas (RCC). Clear-cell RCC is the most common subtype; papillary, chromophobe and rarer types behave differently.
Routine molecular profiling plays a smaller role in kidney cancer than in some other cancers, but histological subtype, risk scores and inherited syndromes are important.
Clinical and molecular questions that often arise
- What is the histological subtype?
- For advanced disease, how is the risk category assessed?
- Do age, bilateral or multiple tumours, or family history suggest an inherited syndrome?
- Are there trials for the specific subtype?
Information that may be part of an individual assessment
- Cross-sectional imaging.
- Histopathology after biopsy or surgery.
- Blood tests that inform risk scores in advanced disease.
- Germline testing where an inherited syndrome is suspected.
Which investigations are appropriate is decided by the treating team for each person.
Molecular profiling and biomarker interpretation
Depending on the setting, molecular and biomarker questions in kidney cancer may involve:
- Histological subtype
- VHL loss (clear-cell RCC)
- FH-deficiency and other subtype-defining changes
- Molecular profiling in rare subtypes
Biomarkers, panels and available tests vary by subtype, disease setting, assay and guideline version. A detected alteration is not automatically actionable.
How KPCIRC pathways may apply
POAS
POAS may help where a rare subtype has been profiled or a report raises questions about trials or inherited findings.
Molecular Tumour Board
MTB discussion may help in complex local or metastatic situations involving urology, oncology and radiology.
Second opinion and progression review
A second opinion may help when weighing surgery, surveillance or systemic options. Progression review can organise imaging and treatment history.
Hereditary risk and screening
Inherited syndromes such as von Hippel–Lindau (VHL), hereditary leiomyomatosis and RCC (FH), Birt–Hogg–Dubé (FLCN) and BAP1 tumour predisposition are associated with kidney cancer. Young age at diagnosis, bilateral tumours or specific subtypes may prompt genetics assessment.
How to access the relevant pathway
Patients and families
- Talk to your treating oncologist about whether an additional review may help.
- Request a consultation and tell us which question you want answered.
- Share records only when asked, through the secure route.
Referring doctors
- Define the clinical question and the pathway: POAS, MTB, second opinion or progression review.
- Start a case enquiry without patient identifiers.
- Scope, fees and timing are confirmed before any review proceeds.
Questions and limitations
Does every kidney cancer need genetic testing?
No. It is considered in specific situations, such as young age, multiple tumours, certain subtypes or a family history.
Why does the subtype matter so much?
Different subtypes behave differently and the relevant evidence differs between them.
Does this page apply to my situation?
This page is educational. It explains common questions but cannot account for individual circumstances. Your treating clinician is best placed to interpret your reports and plan your care.
Educational content reviewed against the KPCIRC service scope. It is not a diagnosis, a treatment recommendation or a statement that a specialist or service is available for this cancer type.